Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Kyowa Hakko Kirin Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kyowa Hakko Kirin Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Kyowa Hakko Kirin Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kyowa Hakko Kirin Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Kyowa Hakko Kirin Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Kyowa Hakko Kirin Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kyowa Hakko Kirin Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kyowa Hakko Kirin Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kyowa Hakko Kirin Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kyowa Hakko Kirin Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kyowa Hakko Kirin Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Kyowa Hakko Kirin Co., Ltd. Snapshot 8
Kyowa Hakko Kirin Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Kyowa Hakko Kirin Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Kyowa Hakko Kirin Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products Glance 19
Kyowa Hakko Kirin Co., Ltd. - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Filing rejected/Withdrawn Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Kyowa Hakko Kirin Co., Ltd. - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Kyowa Hakko Kirin Co., Ltd. - Early Stage Pipeline Products 24
Preclinical Products/Combination Treatment Modalities 24
Discovery Products/Combination Treatment Modalities 25
Kyowa Hakko Kirin Co., Ltd. - Drug Profiles 26
darbepoetin alfa 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
granisetron 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KW-3357 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
mogamulizumab 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
pegfilgrastim 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tivozanib 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
benralizumab 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
brodalumab 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
istradefylline 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
tivantinib 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ASKP-1240 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KHK-4577 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
KRN-23 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
romiplostim 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BIW-8962 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KHK-2823 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KHK-2898 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
KHK-4083 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KHK-6640 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DsiRNA to Inhibit KRAS for Solid Tumor 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DsiRNAs for Solid Tumor 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
K-685 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
K-756 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Ki-26894 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KM-2812 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
KW-6356 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Z-3G1 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Bispecific Antibodies for Undisclosed Indication 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
K-777 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Kyowa Hakko Kirin Co., Ltd. - Pipeline Analysis 69
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Target 69
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Route of Administration 71
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Molecule Type 72
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action 73
Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates 76
Kyowa Hakko Kirin Co., Ltd. - Dormant Projects 95
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products 96
Discontinued Pipeline Product Profiles 96
AGS-003 96
AGS-004 96
anagrelide hydrochloride 97
bardoxolone methyl 97
darbepoetin alfa 97
KHK-2866 97
KHK-6188 97
KRN-330 98
KRX-0601 98
KW-2449 98
KW-2450 98
KW-2478 98
KW-7158 98
litronesib 99
mogamulizumab 99
pibrozelesin hydrobromide 99
tivantinib 99
tivozanib 99
Kyowa Hakko Kirin Co., Ltd. - Company Statement 100
Kyowa Hakko Kirin Co., Ltd. - Locations And Subsidiaries 101
Head Office 101
Other Locations & Subsidiaries 101
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables
Kyowa Hakko Kirin Co., Ltd., Key Information 8
Kyowa Hakko Kirin Co., Ltd., Key Facts 8
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Indication, 2014 11
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Stage of Development, 2014 13
Kyowa Hakko Kirin Co., Ltd. - Monotherapy Products in Pipeline, 2014 14
Kyowa Hakko Kirin Co., Ltd. - Partnered Products in Pipeline, 2014 15
Kyowa Hakko Kirin Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 16
Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products in Pipeline, 2014 17
Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 18
Kyowa Hakko Kirin Co., Ltd. - Pre-Registration, 2014 19
Kyowa Hakko Kirin Co., Ltd. - Filing rejected/Withdrawn, 2014 20
Kyowa Hakko Kirin Co., Ltd. - Phase III, 2014 21
Kyowa Hakko Kirin Co., Ltd. - Phase II, 2014 22
Kyowa Hakko Kirin Co., Ltd. - Phase I, 2014 23
Kyowa Hakko Kirin Co., Ltd. - Preclinical, 2014 24
Kyowa Hakko Kirin Co., Ltd. - Discovery, 2014 25
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Target, 2014 70
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Route of Administration, 2014 71
Kyowa Hakko Kirin Co., Ltd. - Pipeline by Molecule Type, 2014 72
Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 74
Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates, 2014 76
Kyowa Hakko Kirin Co., Ltd. - Dormant Developmental Projects,2014 95
Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products, 2014 96
Kyowa Hakko Kirin Co., Ltd., Other Locations 101
Kyowa Hakko Kirin Co., Ltd., Subsidiaries 102